Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention?

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples